Creative Touch Permanent Makeup and Aesthetics

The Randle Cycle describes the reciprocal competition between glucose and fatty acids for cellular oxidation – when fat is being burned, glucose burning is suppressed, and vice versa. Named after Sir Philip Randle, who published the original mechanism in The Lancet in 1963, it is the biochemical basis of fuel-switching: the cell’s ability to shift cleanly between energy substrates in response to feeding, fasting, and exercise. Metabolic flexibility – the capacity to make this switch efficiently – is now recognised as a meaningful marker of metabolic health, with impaired fuel-switching detectable years before the clinical threshold for type 2 diabetes. The popular science version of the Randle Cycle, which frames it as proof that fat causes insulin resistance, misreads the mechanism in one direction; the equally popular counter-version, which frames it as proof that only sugar is harmful, misreads it in the other. The evidence is more specific and more interesting than either simplification.

The Original 1963 Mechanism

Philip Randle and colleagues published their glucose-fatty acid cycle paper in The Lancet in 1963, working primarily from perfused rat heart models. The core observation was that the relationship between glucose and fatty acid oxidation is reciprocal and competitive: each substrate, when available and being oxidised, chemically suppresses the oxidation of the other. ^[7]

The fatty-acid-suppresses-glucose direction works as follows. When fatty acids are being oxidised, the mitochondrial ratios of acetyl-CoA/ CoA and NADH/NAD⁺ both rise. These increases inhibit pyruvate dehydrogenase (PDH) – the enzyme that commits pyruvate (the end product of glycolysis) to mitochondrial oxidation. Citrate accumulates and leaks into the cytosol, inhibiting phosphofructokinase-1 (PFK-1), the rate-limiting enzyme of glycolysis. Glucose-6-phosphate then accumulates upstream and inhibits hexokinase. The net result: fatty acid oxidation progressively suppresses glucose uptake and utilisation at three sequential points in the glycolytic pathway, with the most severe inhibition at PDH.

The glucose-suppresses-fatty-acid direction is mechanistically distinct. When glucose is abundant and insulin is elevated, glucose oxidation generates citrate, which is converted to malonyl-CoA by acetyl-CoA carboxylase (ACC). Malonyl-CoA potently inhibits CPT-1 (carnitine palmitoyltransferase-1) – the enzyme controlling long-chain fatty acid entry into the mitochondria. Without CPT-1 activity, fatty acids cannot be oxidised; they are rerouted toward esterification instead. Insulin amplifies this effect by suppressing adipose tissue lipolysis and promoting glucose uptake in muscle, forcing the cell toward glucose as its primary fuel. ^[4]

The mechanism itself – both directions – is biochemically confirmed, not disputed, and has been replicated across multiple tissue types. The disputes concern what it means for disease, not whether it operates. ^[2]

The Reinterpretation – What the Randle Cycle Cannot Explain

The original Randle paper proposed that elevated fatty acid oxidation suppressing glucose utilisation was the mechanism behind the impaired glucose disposal seen in insulin resistance and type 2 diabetes. This interpretation – that fat causes insulin resistance by blocking glucose oxidation – became embedded in metabolic disease thinking for decades.

The 2009 review “The Randle Cycle Revisited” systematically challenged this causal application without disputing the underlying biochemistry. The central problem: if fat oxidation blocking glucose oxidation caused insulin resistance, then PPAR agonists – drugs that increase fatty acid oxidation – should improve insulin resistance. They do not consistently do so. The causal direction as originally proposed does not hold. ^[4]

The current mechanistic consensus identifies lipid intermediate accumulation as the operative driver of insulin resistance – specifically diacylglycerol (DAG) and ceramides. These accumulate not from fat oxidation itself but from incomplete fat oxidation in an environment where both fuels are simultaneously elevated: fat cannot enter the mitochondria (CPT-1 inhibited by malonyl-CoA from high glucose/insulin) and therefore accumulates as DAG and ceramides in the cytosol. DAG activates protein kinase C (PKC), which phosphorylates IRS-1 at serine residues rather than tyrosine residues – impairing insulin receptor substrate signalling and blocking the insulin cascade downstream. Ceramides additionally impair Akt signalling, a second major route to insulin resistance. ^[8]

This is related to the original Randle mechanism but is not the same thing. The Randle cycle describes the fuel competition biochemistry correctly; the lipotoxicity/DAG/ceramide model describes the downstream impairment of insulin signalling that produces insulin resistance. The 2009 review concluded that the Randle cycle “may not be the primary mechanism” of insulin resistance as originally proposed, but remains valid as a description of normal fuel-switching physiology. ^[4]

Clinical Pearl The framing matters for dietary discussions. Fat per se does not cause insulin resistance through the Randle mechanism – incomplete fat oxidation in a metabolically compromised, glucose-saturated environment does. The distinction between “fat causes insulin resistance” and “lipid intermediates from a metabolic impasse cause insulin resistance” is not a technical nicety; it changes the dietary implications substantially.

Metabolic Flexibility – The Clinical Frame

The most productive clinical application of Randle Cycle biology is not the causal direction debate but the concept of metabolic flexibility: the ability to switch cleanly between glucose and fat oxidation in response to physiological signals.

Metabolically healthy individuals switch efficiently. During fasting and between meals, falling insulin and rising glucagon promote lipolysis; fatty acids become the dominant fuel; the Randle mechanism suppresses unnecessary glucose oxidation, preserving glucose for tissues that require it (notably the brain). After eating, rising glucose and insulin reverse the process: malonyl-CoA rises, CPT-1 is inhibited, fat oxidation yields to glucose oxidation, and the fed-state energy surplus is appropriately managed. During aerobic exercise, fatty acid mobilisation from adipose tissue increases while glucose is conserved – the Randle switch operating in the fat-preferring direction under conditions of energy demand. ^[6]

Clinical evidence supports this. A 2025 review found that appetite does not increase despite weight loss as long as individuals maintain nutritional ketosis – and that hunger rebounds when carbohydrates are reintroduced. ^[3] This aligns directly with the CPT-1/malonyl-CoA mechanism: ketosis indicates low competing glucose signal, uninhibited fat entry into the mitochondria, and clean fuel commitment. The restoration of this clean commitment is, on the mechanistic account, what distinguishes ketosis from conventional calorie restriction as a weight maintenance approach.

Metabolic inflexibility describes failure of this switching. In early insulin resistance, the cell becomes progressively less responsive to the hormonal signals that prompt fuel switching. The most characteristic pattern is a failure to fully suppress fat oxidation in the fed state and a failure to fully suppress glucose oxidation in the fasted state – the cell becomes stuck in an intermediate, inefficient metabolic mode. This is measurable using the respiratory quotient (RQ): a metabolically flexible person shifts from an RQ of approximately 0.7 (fat oxidation predominating) in the fasted state toward 1.0 (glucose oxidation predominating) after a carbohydrate-containing meal; a metabolically inflexible person shows a blunted fasting-to-fed shift. ^[4]

This impairment is detectable years before the clinical threshold for type 2 diabetes is reached. Metabolic inflexibility is, in this sense, an early functional marker of the insulin resistance trajectory – and one that is reversible, particularly through dietary carbohydrate reduction, which removes the malonyl-CoA/CPT-1 block and allows fat oxidation to re-establish. youtube

Why the Fat + Sugar Combination Is Specifically Harmful

The most clinically useful insight the Randle Cycle provides – and the one most underrepresented in accessible health content – is why the simultaneous delivery of fat and sugar is metabolically distinct from either macronutrient in isolation.

The comparison runs as follows:

High fat / low carbohydrate – insulin low, malonyl-CoA low, CPT-1 uninhibited, fatty acids enter mitochondria and are oxidised cleanly. The Randle mechanism suppresses glucose oxidation appropriately. Metabolic flexibility maintained; no lipid intermediate accumulation.

High carbohydrate / low fat – insulin elevated, malonyl-CoA high, CPT-1 inhibited, fat oxidation suppressed. But glucose is available and being used; one fuel pathway running cleanly. Insulin resistance risk accumulates over time with chronic hyperinsulinaemia, but the metabolic pathway is not in impasse.

High fat + high sugar simultaneously – the profile characteristic of ultra-processed foods: glucose drives insulin drives malonyl-CoA drives CPT-1 inhibition → incoming dietary fat cannot enter the mitochondria → fat accumulates as DAG and ceramides → IRS-1 serine phosphorylation → insulin signalling impaired → glucose oxidation also progressively impaired → neither fuel is being handled cleanly. This is the metabolic impasse that generates lipotoxicity through the lipid intermediate route.

This explains a finding that pure macronutrient-category thinking cannot: both low-fat/high-carbohydrate and high-fat/low-carbohydrate dietary patterns have clinical evidence of metabolic benefit, while the typical Western ultra-processed food pattern – moderate fat and high refined carbohydrate delivered simultaneously – produces the worst metabolic outcomes. The critical variable is not which macronutrient predominates but whether the cell is able to make a clean fuel commitment. When both are chronically elevated together, it cannot.

The metabolic significance of this combination is compounded behaviourally: restriction-induced ghrelin surges specifically intensify cravings for fat and sugar together – the precise combination that the Randle mechanism identifies as most metabolically disruptive. The dietary stress response and the cellular impasse it produces are, in this sense, self-reinforcing.

Clinical Pearl This is the mechanistic basis for why food quality – and specifically UPF avoidance – matters independently of macronutrient ratios. A whole food omnivorous diet and a whole food plant-based diet may deliver very different macronutrient profiles, but both avoid the simultaneous high sugar and UPF consumption pattern that creates the metabolic impasse. The Randle Cycle provides a cellular-level explanation for an observation that epidemiology has established at the population level.

The metabolic impasse has a further consequence that the lipid intermediate pathway does not capture. The Hue and Taegtmeyer review establishes that the initial event of fatty acid oxidation is an increase in the mitochondrial NADH/NAD⁺ ratio – and in the impasse, NADH accumulates from two concurrent sources simultaneously. ^[4] This sustained reduction in the NAD⁺/NADH ratio depletes the cellular NAD⁺ pool available to SIRT1, a NAD⁺-dependent deacetylase that is required to sustain the amplitude of the molecular circadian clock in skin cells. When SIRT1 activity stalls through NAD⁺ insufficiency, the BMAL1 oscillation amplitude dampens – weakening the circadian gating that controls ceramide synthesis timing, the collagen synthesis-assembly sequence in fibroblasts, and DNA repair efficiency across the day-night cycle. The lipid intermediate route and the NAD⁺/circadian route are therefore two distinct downstream consequences of the same metabolic impasse, operating in parallel rather than sequentially. The mechanisms, evidence base, and clinical implications of this second route are documented in the Metabolic Chronodisruption page.

What the Evidence Does and Does Not Show

The Randle Cycle has been recruited into several popular science narratives that outrun the evidence in different directions. For the purposes of this knowledge base, the honest calibration is as follows:

Established and not disputed:

• The reciprocal inhibition biochemistry (both directions) is confirmed across multiple tissue types and experimental models
• Metabolic flexibility as a measurable phenotype is validated by RQ measurement and indirect calorimetry
• Metabolic inflexibility precedes T2DM and correlates with insulin resistance severity
• DAG and ceramides as the operative lipotoxicity mechanism impairing insulin signalling is well-evidenced primary research ^[8]

Well-supported but requiring synthesis across sources:

• The “fat + sugar combination is specifically harmful” argument is mechanistically coherent and supported by the individual mechanistic components, but no single study frames it as cleanly as the entity does here. It is an interpretive synthesis with strong mechanistic grounding, not a single-paper finding.
• Low-carbohydrate dietary intervention restoring metabolic flexibility is supported by clinical evidence – notably an 8-year NHS service evaluation [Unwin et al. 2023] and the TOWARD multimodal intervention study , both showing sustained weight loss and metabolic improvement through therapeutic carbohydrate reduction without ongoing pharmacological appetite suppression. ^{[9] [1]}
• The metabolic impasse generating sustained NAD⁺ depletion sufficient to reduce SIRT1 activity and circadian clock amplitude – each link in this chain is confirmed in primary research; the complete chain in skin cells specifically is an interpretive synthesis across those independently established links. Documented in full with evidence tier ratings in the Metabolic Chronodisruption page.

Directionally correct but oversimplified:

• “The Randle Cycle proves fat doesn’t cause insulin resistance” – directionally correct but strips out the lipid intermediate mechanism, which does implicate fat accumulation (from incomplete oxidation) in the causal chain
• “The Randle Cycle proves carbohydrate causes insulin resistance” – oversimplified; chronic hyperinsulinaemia is the proximate driver of CPT-1 inhibition; the carbohydrate-insulin connection is mediated, not direct